BR100 Decreased By (-0.08%)
BR30 Increased By (0.08%)
KSE100 Decreased By (-0.11%)
KSE30 Decreased By (-0.2%)
AGHA 7.53 Decreased By ▼ -0.10 (-1.31%)
BECO 5.11 Decreased By ▼ -0.46 (-8.26%)
BML 58.30 Decreased By ▼ -1.44 (-2.41%)
BOP 34.58 Increased By ▲ 0.18 (0.52%)
CNERGY 13.68 Increased By ▲ 0.57 (4.35%)
CSIL 6.30 Decreased By ▼ -0.11 (-1.72%)
FCCL 57.55 Decreased By ▼ -0.51 (-0.88%)
FFL 16.50 Increased By ▲ 0.27 (1.66%)
FNEL 1.20 Decreased By ▼ -0.01 (-0.83%)
KEL 7.36 Decreased By ▼ -0.07 (-0.94%)
KOSM 5.98 Decreased By ▼ -0.05 (-0.83%)
LOTCHEM 27.51 Decreased By ▼ -0.16 (-0.58%)
MLCF 101.93 Decreased By ▼ -0.82 (-0.8%)
NBP 203.29 Decreased By ▼ -1.77 (-0.86%)
NCPL 60.47 Increased By ▲ 0.84 (1.41%)
NPL 69.80 Increased By ▲ 1.24 (1.81%)
OGDC 318.48 Decreased By ▼ -0.44 (-0.14%)
PACE 11.12 Increased By ▲ 0.07 (0.63%)
PAEL 42.86 Decreased By ▼ -0.24 (-0.56%)
PIBTL 16.72 Increased By ▲ 0.09 (0.54%)
PPL 230.62 Increased By ▲ 1.17 (0.51%)
PRL 76.73 Increased By ▲ 5.93 (8.38%)
PTC 71.18 Increased By ▲ 0.18 (0.25%)
SSGC 27.10 Decreased By ▼ -0.31 (-1.13%)
TBL 10.28 Decreased By ▼ -0.03 (-0.29%)
TELE 8.56 Increased By ▲ 0.03 (0.35%)
TPL 23.59 Increased By ▲ 0.53 (2.3%)
TPLP 15.45 Decreased By ▼ -0.31 (-1.97%)
TREET 24.51 Decreased By ▼ -0.20 (-0.81%)
TRG 60.09 Decreased By ▼ -0.20 (-0.33%)

KARACHI: In violation of the Sindh Drug Rules, pharmaceutical manufacturers and distributors have expressed dismay over not being invited to an upcoming scheduled meeting of the Sindh Quality Control Board (SCQB), prompting concerns over transparency and regulatory fairness, Business Recorder has learnt.

In a formal letter to the Sindh Health Department, PCDA Secretary General M Asim Jamil expressed disappointment that the association, despite being the only registered trade body representing chemists, druggists, importers, and distributors, was not invited to participate in the Board’s scheduled meeting.

He emphasised that under the Sindh Drug Rules (Amended) 2010, relevant trade bodies must be consulted on matters related to pharmaceutical regulation.

“It has come to our attention that meetings of the SCQB are being scheduled, but PCDA has not been invited despite being a key stakeholder,” the letter read. “This raises concerns regarding transparency and fairness in the Board’s decision-making.”

PCDA also noted that the PPMA, which represents local drug manufacturers, had similarly been excluded from attending as an observer, further intensifying industry apprehensions about the lack of representation in regulatory proceedings that directly impact their operations.

Calling for immediate rectification, PCDA urged the Health Secretary to ensure the inclusion of both associations in future SCQB meetings to uphold fair practices and regulatory clarity.

Copyright Business Recorder, 2025

Comments

Comments are closed for this article.